EVOQ Remedies Peer Comparison

BSE: 543500

₹1.46

₹-0.07 (-4.58%)

As on 29-Sep-2026 12:22IST

Market cap

₹4 Cr

Revenue (TTM)

₹12 Cr

P/E Ratio

--

P/B Ratio

0.1

Div. Yield

0 %

Edit

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	4	21,268	20,341	18,071	16,687
Revenue (₹ Cr)	12	2,287	1,682	2,570	3,230
Net Profit (₹ Cr)	0.09	678.07	273.51	735.15	666.92
Net Margin (%)	0.62	28.10	16.19	26.88	20.60
RoE (%)	0.25	19.73	11.15	19.16	18.75
Price to Earnings	--	31.96	68.41	24.58	25.91
Price-To-Book	0.08	5.79	7.57	4.10	4.14

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	11.76	1,937.47	1,286.43	2,281.35	2,893.64
Total Income	14.17	2,033.90	1,322.88	2,453.60	2,912.00
Total Expenditure	13.99	1,290.54	980.18	1,541.03	1,876.44
EBITDA	-2.24	646.93	306.25	740.32	1,017.20
Depreciation	0.05	65.96	112.99	60.79	315.46
EBIT	-2.29	580.97	193.26	679.53	701.74
Interest	--	0.61	75.53	8.50	231.29
Other Income	2.41	96.43	36.45	172.25	18.36
Exceptional Items	--	--	-30.58	172.81	--
Profit before Tax	0.13	676.78	122.33	1,016.09	488.87
Provision for Tax	0.04	135.69	44.04	248.49	114.20
Profit after Tax	0.09	541.09	78.29	767.60	374.67

Liabilities (₹ Cr)

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	44.54	2,850.49	2,362.70	4,217.41	2,854.36
Minority Interest	--	35.90	1.04	--	417.40
Non-Current Liabilities	--	13.24	259.78	54.89	2,100.97
Current Liabilities	5.47	305.99	674.19	569.51	1,492.79
Total Liabilities	50.01	3,207.85	3,310.68	4,911.11	6,865.52

Assets (₹ Cr)

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	0.22	1,071.67	2,313.20	1,328.96	5,531.13
Current Assets	49.79	2,133.95	984.51	3,512.85	1,334.39
Total Assets	50.01	3,207.85	3,310.68	4,911.11	6,865.52
Total Debt*	0.00	0.55	586.37	2.50	2,421.66
Net Current Assets	44.31	1,827.96	310.32	2,943.34	-158.40
Contingent Liabilities	6.55	0.64	76.22	363.79	51.96

Cashflow (₹ Cr)

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	-14.62	432.37	132.27	659.75	1,065.01
Cash Flow from Investing Activities	-0.26	-334.73	-199.13	-71.34	-79.97
Cash from Financing Activities	14.97	-38.32	62.65	-205.34	-881.32
Net Cash Inflow / Outflow	0.09	59.32	-4.21	383.07	103.72

Ratios

Profitability Ratios

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	0.35	26.22	6.95	26.21	13.59
ROE (%)	0.25	21.72	3.75	19.65	13.81
ROA (%)	0.20	18.37	2.45	17.03	5.48
EBIT Margin (%)	1.51	38.37	26.64	40.00	35.79
Net Margin (%)	0.62	26.60	5.92	31.28	12.87
Cash Profit Margin (%)	1.17	31.33	14.87	34.70	23.21

Growth Ratios

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	190.11	14.37	11.71	4.02	44.02
EBIT Growth (%)	-71.38	20.21	35.64	11.86	48.22
Net Profit Growth (%)	-80.50	17.27	145.00	39.23	-5.65
EPS Growth (%)	-89.36	17.25	118.00	39.23	-10.39
Book Value Growth (%)	76.47	23.77	30.63	17.30	10.19

Valuation Ratios

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	72.32	28.38	41.41	23.86	54.83
Price / Book Value	0.14	5.52	2.74	4.34	6.78
Dividend Yield (%)	0.00	0.30	0.15	4.12	0.52
EV/EBITDA	34.78	19.78	20.55	17.01	20.75
Market Cap (₹ Cr)	6.37	15,219.80	6,484.12	18,318.10	19,292.77

Solvency Ratios

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.00	0.25	0.00	0.85
Short term debt to equity ratio	--	0.00	0.13	0.00	0.14
Current Ratio	9.10	6.97	1.46	6.17	0.89
Quick Ratio	8.69	5.88	0.94	5.33	0.67
Interest Coverage	--	1,110.48	2.62	120.54	3.11

Operating Efficiency Ratios

	EVOQ Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	73.29	32.65	34.26	8.46	15.85
Asset Turnover	0.27	0.66	0.40	0.53	0.43
Receivable days	160.81	110.70	118.15	29.10	54.06
Inventory Days	82.96	65.86	98.29	69.53	32.16
Payable days	94.59	105.88	128.16	76.77	140.91
Cash Conversion Cycle	149.18	70.68	88.28	21.86	-54.69

Annual
Quarterly